Korean Gene, Cell Therapies Edge Ahead In Challenging Environment

Despite the challenges in the sector, South Korean biotech companies are making substantial progress in the gene and cell therapy space, with several companies set to begin or already in late stage clinical trials at home and abroad, stepping gradually towards commercialization.

SEOUL - The stem cell and gene therapy market is forecast to grow rapidly with large pharma firms beginning to pay strong attention to the sector, although the industry still needs to overcome challenges such as tough regulations, high prices of therapies, lack of target patients and worries over safety and efficacy of the drugs.

The era of third generation biomedicines including gene and cell therapies appears to have started, with R&D activities in this sector in South Korea and more broadly becoming active in recent years, although some experts are still skeptical as to whether the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By 

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By 

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By 

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By 

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

More from Focus On Asia